Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 7/20 | 0.47 |
| ▸ | HTR2C | P28335 | 7/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633399 | 0.97 | DRD2 (0.58) | DRD2DRD3ADRA1ADRD4MEN1 | |
| SCHEMBL16633469 | 0.83 | DRD2 (0.59) | DRD2DRD3ADRA1ADRD4HTR2A | |
| SCHEMBL16634117 | 0.83 | DRD2 (0.54) | DRD2DRD3ADRA1ADRD4HTR2A | |
| SCHEMBL13499598 | 0.83 | DRD2 (0.51) | DRD2DRD3HTR2AHTR7 | |
| SCHEMBL16633483 | 0.81 | DRD2 (0.59) | DRD2DRD3ADRA1ADRD4HTR2A | |
| SCHEMBL16633520 | 0.80 | DRD2 (0.59) | DRD2DRD3ADRA1ADRD4HTR2A | |
| SCHEMBL29785732 | 0.80 | DRD2 (0.54) | DRD2DRD3DRD4MEN1ALDH1A1 | |
| SCHEMBL15326107 | 0.78 | HTR7 (0.52) | DRD2DRD3MEN1ALDH1A1KMT2A | |
| SCHEMBL16633146 | 0.77 | KCNH2 (0.58) | DRD2DRD3DRD4KMT2AHTR2A | |
| SCHEMBL12441085 | 0.76 | MEN1 (0.60) | DRD2DRD3ADRA1ADRD4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238632-B2 | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | NHWA Pharma, Corporation (CN) | 2016-01-19 | — | — | US | claimed |
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-04-16 | — | — | US | claimed |
| US-9238632-B2 | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | NHWA Pharma, Corporation (CN) | 2016-01-19 | — | — | US | disclosed |
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | HTR5A, HTR3C, HTR3A | DRD2 80/4885DRD3 57/4885ADRA1A 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.